Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Complete title: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias (ENVISION-AHP)

Research Study Number 20172377
Principal Investigator Sioban Keel, MD
Phase III

Research Study Description

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20172377
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Digestive System Diseases; Genetic Diseases, Inborn; Metabolic Diseases; Skin Diseases; Liver Diseases; Porphyrias; Porphyria, Erythropoietic; Porphyria, Acute Intermittent; Porphyrias, Hepatic; Coproporphyria, Hereditary; Porphyria, Variegate; Skin Diseases, Genetic

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials